GEO DataSets

Analysis of peripheral blood and bone marrow of chronic myelogenous leukemia (CML) patients prior to imatinib (Gleevec) treatment. Imatinib induces complete cytogenetic response (CCR) in most CML patients. This study attempts to determine transcriptional signature of imatinib non-responders.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 cell type, 2 other sets

Platform:

GPL8300

Series:

GSE2535

28 Samples

Download data: CEL

(Submitter supplied) This is a class prediction experiment, where the class is the response status to imatinib (also called Gleevec), a drug used to treat patients with chronic myelogenous leukemia (CML). There are two data sets, a training set (from Leipzig, 8 Responders and 5 Non-Responders) and a validation set (from Mannheim, 8 Responders and 7 Non-Responders). The objective is to identify differentially regulated genes between CML patients who respond and those who do not respond to imatinib and confirm the results in the validation data set. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS1221

Platform:

GPL8300

28 Samples

Download data: CEL

(Submitter supplied) Newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with a major cytogenetic response (MCyR) after 12 months of imatinib therapy have an excellent long-term outcome, while patients without MCyR have a high progression risk. Since patients with primary cytogenetic resistance may benefit from more intensive therapy up-front, we sought to identify biomarkers to predict MCyR. Keywords: Two group comparison to identify trasncriptomic signature that predicts response to therapy

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

59 Samples

Download data: CEL